Entrada Therapeutics, Inc. $TRDA Stock Holdings Increased by JPMorgan Chase & Co.

Key Points

• JPMorgan Chase raised its stake in Entrada Therapeutics by 735% in Q3 to 133,878 shares (about 0.35% of the company), increasing holdings by 117,844 shares and valuing its position at roughly $776,000.
• Entrada shares trade around $13.50 (down 3.9%), with a market cap of $516.8M, a 52-week range of $4.93–$14.36, negative profitability (EPS of -$0.94 this quarter) and a consensus analyst rating of Moderate Buy
• Corporate insiders have been selling recently—CFO and COO sold shares on March 10 and insiders disposed of 41,975 shares worth ~$540,444 over the past 90 days—while institutional investors own about 86.4% of the stock.

JPMorgan Chase & Co. raised its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 735.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,878 shares of the company's stock after acquiring an additional 117,844 shares during the period. JPMorgan Chase & Co. owned approximately 0.35% of Entrada Therapeutics worth $776,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming raised its stake in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after acquiring an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth $68,000. IHT Wealth Management LLC bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth $72,000. Finally, AXQ Capital LP bought a new stake in shares of Entrada Therapeutics in the 3rd quarter worth $67,000. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Stock Down 3.9%

Shares of NASDAQ TRDA opened at $13.50 on Friday. The stock has a market capitalization of $516.78 million, a price-to-earnings ratio of -3.90 and a beta of -0.15. The stock's fifty day simple moving average is $12.06 and its 200 day simple moving average is $9.99. Entrada Therapeutics, Inc. has a 52-week low of $4.93 and a 52-week high of $14.36.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million for the quarter, compared to analysts' expectations of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on TRDA shares. Oppenheimer boosted their price objective on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an "outperform" rating in a research note on Monday, April 6th. Guggenheim raised Entrada Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 11th. Weiss Ratings reissued a "sell (d)" rating on shares of Entrada Therapeutics in a research note on Friday, March 27th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Finally, Wall Street Zen downgraded Entrada Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Entrada Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $19.00.

Insiders Place Their Bets

In related news, CFO Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $13.02, for a total value of $148,271.76. Following the transaction, the chief financial officer directly owned 121,510 shares in the company, valued at $1,582,060.20. The trade was a 8.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Nathan J. Dowden sold 11,894 shares of Entrada Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total value of $155,216.70. Following the completion of the transaction, the chief operating officer owned 198,588 shares in the company, valued at $2,591,573.40. The trade was a 5.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 41,975 shares of company stock worth $540,444 over the last 90 days. Insiders own 8.11% of the company's stock.

About Entrada Therapeutics

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.